| 59559-5 |
Collaborative staging pre treatment extension |
Prid |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Collaborative staging pre treatment extension Cancer |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
TUMRRGT |
|
59559-5 |
|
|
|
|
|
|
|
|
0 |
CS pre Rx ex Cancer |
|
|
|
N |
|
Before; CA; CS; CS pre Rx ex; EXT; Identity or presence; Misc; Miscellaneous; Nominal; Oncology; Other; Point in time; Random; Spec; To be specified in another part of the message; TUMOR REGISTRY(NAACCR); Tx; Unspecified |
2.34 |
2.34 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 5956-8 |
Coagulation tissue factor induced.factor substitution^immediately after addition of normal plasma |
Time |
PPP^Control |
Pt |
Qn |
Coag |
|
ACTIVE |
Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --immediately after addition of normal plasma |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
5956-8 |
|
Coag |
|
|
Observation |
|
|
|
0 |
PT imm NP Cont PPP |
|
|
|
Y |
|
Clot; Clottable; Coag; Coagulation assay; Contrl; Control; Fac; Fact; Hematology; Heme; imm NP; Immediatedly after 1:1 addition of; Mixing studies; Normal; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random; Tilt tube |
2.73 |
1.0d |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 59560-3 |
Surgical approach at facility.YYY 2010 |
Prid |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Surgical approach at facility.YYY 2010 Cancer |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
TUMRRGT |
|
59560-3 |
|
|
|
|
|
|
|
|
0 |
Surg app at facility 2010 Cancer |
|
|
|
N |
|
CA; Identity or presence; Misc; Miscellaneous; Nominal; Oncology; Other; Point in time; Random; Spec; Surg; Surg app at facility 2010; To be specified in another part of the message; TUMOR REGISTRY(NAACCR); Unspecified |
2.34 |
2.34 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 59561-1 |
Propofol glucuronide |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Propofol glucuronide [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59561-1 |
|
|
|
|
Both |
|
|
|
0 |
Propofol glucuronide Ur-mCnc |
|
|
|
N |
|
CPRO; Diprivan; Diprivan metabolite; Disoprivan; DRUG/TOXICOLOGY; Drugs; Gluc; Glucouronide; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Rapinovet; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 59562-9 |
DNA index |
AreaRto |
Cells.XXX |
Pt |
Qn |
Automated image cytometry |
|
ACTIVE |
DNA index by Automated image cytometry |
|
MIN |
DefinitionDescription |
|
|
|
|
|
DNA index = DNA abnormal cell/DNA normal cell |
|
|
|
MOLPATH |
|
59562-9 |
|
Automated image cytometry |
|
|
Both |
|
|
|
0 |
DNA Index Auto cyto |
|
|
|
N |
|
Area Ratio; Auto; Auto cyto; Automated detection; Deoxyribonucleic acid; DI; DNA score; Elec; Elect; Electr; Misc; Miscellaneous; Molecular pathology; MOLPATH; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
Based on original communication regarding this term, the component was edited. |
0 |
| 59563-7 |
Protein.monoclonal band 4 |
MCnc |
Urine |
Pt |
Qn |
Electrophoresis |
|
ACTIVE |
Protein.monoclonal band 4 [Mass/volume] in Urine by Electrophoresis |
|
MIN |
DefinitionDescription |
|
|
g/L |
|
|
|
|
|
|
CHEM |
|
59563-7 |
|
Electrophoresis |
|
|
Observation |
|
|
|
0 |
M Protein 4 Ur Elph-mCnc |
|
|
|
N |
|
Bands; bnd; Chemistry; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; Kidney; Level; M Protein; M Protein 4; Mass Concentration; M-band; Monoclonal band; Monoclonal spike; M-protein; M-spike; Nephrology; Para protein; Paraprotein; PEUR; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UPEP; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
g/L |
|
|
|
0 |
| 59564-5 |
Alpha-1-Fetoprotein |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Alpha-1-Fetoprotein [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
CHEM |
|
59564-5 |
|
|
|
|
Both |
|
|
|
0 |
AFP CSF-aCnc |
|
|
|
N |
|
A1; AFP; Alfa; Alpha fetoprotein; Alphafetoprotein; Arbitrary concentration; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; Feto; i; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Tumor marker |
2.7 |
2.32 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
| 59565-2 |
Netilmicin^trough |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Netilmicin [Moles/volume] in Serum or Plasma --trough |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
59565-2 |
|
|
|
|
Both |
|
|
|
0 |
Netilmicin Trough SerPl-sCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; ID; Infectious Disease; InfectiousDisease; Level; Netilimicin; Netromycin; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.32 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 59566-0 |
Netilmicin |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Netilmicin [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
59566-0 |
|
|
|
|
Both |
|
|
|
0 |
Netilmicin SerPl-sCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Netilimicin; Netromycin; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.32 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 59567-8 |
Netilmicin^peak |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Netilmicin [Moles/volume] in Serum or Plasma --peak |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
DRUG/TOX |
|
59567-8 |
|
|
|
|
Both |
|
|
|
0 |
Netilmicin Peak SerPl-sCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; ID; Infectious Disease; InfectiousDisease; Level; Netilimicin; Netromycin; Pl; Plasma; Plsm; Point in time; Post; Postdose; Post-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.32 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 59568-6 |
Orotate |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Orotate [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
umol/24 H |
|
|
|
|
|
|
CHEM |
|
59568-6 |
|
|
|
|
Both |
|
|
|
0 |
Orotate 24h Ur-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Orotic acid; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
umol/(24.h) |
|
|
|
0 |
| 59569-4 |
Calcitonin^post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Calcitonin [Moles/volume] in Serum or Plasma --post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
59569-4 |
|
|
|
|
Observation |
|
|
|
0 |
Calcit p chal SerPl-sCnc |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; CT; Level; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Thyrocalcitonin; Tumor marker |
2.7 |
2.32 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 5957-6 |
Coagulation tissue factor induced.factor substitution^20M post incubation after addition of normal plasma |
Time |
PPP |
Pt |
Qn |
Coag |
|
ACTIVE |
Prothrombin time (PT) factor substitution in Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma |
|
MIN |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
5957-6 |
|
Coag |
|
|
Observation |
|
|
|
0 |
PT 20M NP PPP |
|
|
|
Y |
|
20M NP; 20M p Inc; After; Clot; Clottable; Coag; Coagulation assay; Control; Fac; Fact; Hematology; Heme; Mixing studies; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PST; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random; Tilt tube |
2.44 |
1.0d |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 59570-2 |
Urea nitrogen |
SCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Urea nitrogen [Moles/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
59570-2 |
|
|
|
|
Both |
|
|
|
0 |
BUN Bld-sCnc |
|
|
|
N |
|
Blood; Blood urea nitrogen; BUN; Chemistry; Kidney; Level; N; N2; Nephrology; Nit; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Substance Concentration; UN; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 59571-0 |
Triglyceride |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Triglyceride [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/D |
|
|
|
|
|
|
CHEM |
|
59571-0 |
|
|
|
|
Both |
|
|
|
0 |
Trigl 24h Ur-sRate |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; Tg; Trig; Trigly; Triglycerides; Triglycrides; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
| 59572-8 |
Triglyceride |
SCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Triglyceride [Moles/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
59572-8 |
|
|
|
|
Both |
|
|
|
0 |
Trigl Ur-sCnc |
|
|
|
N |
|
Chemistry; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; Tg; Trig; Trigly; Triglycerides; Triglycrides; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 59573-6 |
Cannabinoids |
PrThr |
Gast fld |
Pt |
Ord |
|
|
ACTIVE |
Cannabinoids [Presence] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
59573-6 |
|
|
|
|
Both |
|
|
|
0 |
Cannabinoids Gast Ql |
|
|
|
N |
|
Addiction; Cannabinoid; Delta-9-tetrahydrocannabinol; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GAST; Gastric contents; Gastric fluid; Illicit; Marijuana; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; THC |
2.56 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 59574-4 |
Body mass index |
Prctl |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Body mass index (BMI) [Percentile] |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
BDYWGT.MOLEC |
|
59574-4 |
|
|
|
|
|
|
|
|
0 |
BMI Prctl |
|
|
|
N |
|
BMI; bod; Bodies; BODY WEIGHT.MOLEC; Percentile; Point in time; QNT; Quan; Quant; Quantitative; Quetelet index; Random |
2.73 |
2.32 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 59575-1 |
Body mass index |
Prctl |
^Patient |
Pt |
Qn |
Per age |
|
ACTIVE |
Body mass index (BMI) [Percentile] Per age |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
BDYWGT.MOLEC |
|
59575-1 |
|
Per age |
|
|
|
|
|
|
0 |
BMI Prctl Per Age |
|
|
|
N |
|
BMI; bod; Bodies; BODY WEIGHT.MOLEC; Percentile; Point in time; QNT; Quan; Quant; Quantitative; Quetelet index; Random |
2.48 |
2.32 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 59576-9 |
Body mass index |
Prctl |
^Patient |
Pt |
Qn |
Per age and sex |
|
ACTIVE |
Body mass index (BMI) [Percentile] Per age and sex |
|
MAJ |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
BDYWGT.MOLEC |
|
59576-9 |
|
Per age and sex |
|
|
|
|
|
|
0 |
BMI Prctl Per age+sex |
|
|
|
N |
|
BMI; bod; Bodies; BODY WEIGHT.MOLEC; Gender; Per age+sex; Percentile; Point in time; QNT; Quan; Quant; Quantitative; Quetelet index; Random |
2.66 |
2.32 |
|
|
|
|
|
|
|
% |
|
|
Updated "Gender" to "Sex" in Method to to correctly represent the concept based on WHO definitions of sex and gender |
0 |
| 59577-7 |
Glucagon^7th specimen post CFst |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucagon [Mass/volume] in Serum or Plasma --7th specimen fasting |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
Numeric |
|
|
|
|
|
CHAL |
|
59577-7 |
|
|
|
|
Observation |
|
|
|
0 |
Glucagon sp7 p fast SerPl-mCnc |
|
|
|
N |
|
After; Calorie Fast; CHEMISTRY.CHALLENGE TESTING; Fast; Fasting; HGF; Hyperglycemic factor; Level; Mass concentration; p fast; PC; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp7; sp7 p fast; Spec; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 59578-5 |
Glucagon^6th specimen post CFst |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucagon [Mass/volume] in Serum or Plasma --6th specimen fasting |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
Numeric |
|
|
|
|
|
CHAL |
|
59578-5 |
|
|
|
|
Observation |
|
|
|
0 |
Glucagon sp6 p fast SerPl-mCnc |
|
|
|
N |
|
After; Calorie Fast; CHEMISTRY.CHALLENGE TESTING; Fast; Fasting; HGF; Hyperglycemic factor; Level; Mass concentration; p fast; PC; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp6; sp6 p fast; Spec; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 59579-3 |
Coxsackievirus A24 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A24 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Negative Titer results (i.e. 1:2, 1:4, etc.) |
|
|
|
|
|
MICRO |
|
59579-3 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A24 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A24; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 5958-4 |
Coagulation tissue factor induced.factor substitution^20M post incubation after addition of normal plasma |
Time |
PPP^Control |
Pt |
Qn |
Coag |
|
ACTIVE |
Prothrombin time (PT) factor substitution in Control Platelet poor plasma by Coagulation assay --20M post incubation with normal plasma |
|
MAJ |
DefinitionDescription |
|
|
s |
|
|
|
|
|
|
COAG |
|
5958-4 |
|
Coag |
|
|
Observation |
|
|
|
0 |
PT 20M NP Cont PPP |
|
|
|
Y |
|
20M NP; 20M p Inc; After; Clot; Clottable; Coag; Coagulation assay; Contrl; Control; Fac; Fact; Hematology; Heme; Mixing studies; Normal; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PST; PT; PT correction study; PT immediate mix; PT incubated mix; QNT; Quan; Quant; Quantitative; Random; Tilt tube |
2.44 |
1.0d |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 59580-1 |
Coxsackievirus A16 Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Coxsackievirus A16 IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
Negative Titer results (i.e. 1:2, 1:4, etc.) |
|
|
|
|
|
MICRO |
|
59580-1 |
|
IF |
|
|
Both |
|
|
|
0 |
CV A16 IgM Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A16; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; Ttr |
2.75 |
2.32 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
